Abstracts tagged "quality improvement"

Abstract Number: 0256 • ACR Convergence 2021
Consensus Approach to a Treat to Target Strategy in Juvenile Idiopathic Arthritis Care: Report from the 2020 Pediatric Rheumatology Care and Outcomes Improvement Network Consensus Conference
Tala El Tal¹, Meghan Ryan², Brian Feldman³, Catherine Bingham⁴, Jon Burnham⁵, Michelle Batthish⁶, Danielle Bullock⁷, Kerry Ferraro⁸, Mileka Gilbert⁹, Beth Gottlieb¹⁰, Julia Harris¹¹, Melissa Hazen¹², Ronald Laxer¹³, Tzielan Lee¹⁴, Daniel Lovell¹⁵, Melissa Mannion¹⁶, Laura Noonan¹⁷, Edward Oberle¹⁸, Anne Paul¹⁹, Janalee Taylor²⁰, Jennifer Weiss²¹, Cagri Yildirim-Toruner²² and Esi Morgan²³, ¹University of Toronto/Hospital for Sick Children, Toronto, ON, Canada, ²University of Minnesota, Vadnais Heights, MN, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴Penn State Children's Hospital, Allentown, PA, ⁵Children's Hospital of Philadelphia, Philadelphia, PA, ⁶McMaster University, Hamilton, ON, Canada, ⁷University of Minnesota, Minneapolis, MN, ⁸Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, ⁹Medical University of South Carolina, Charleston, SC, ¹⁰Cohen Children's Medical Center, Lake Success, NY, ¹¹Children's Mercy Kansas City, Overland Park, KS, ¹²Boston Children's Hospital, Boston, MA, ¹³SickKids, Toronto, ON, Canada, ¹⁴Stanford University School of Medicine, Palo Alto, CA, ¹⁵Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH, ¹⁶University of Alabama at Birmingham, Birmingham, AL, ¹⁷Levine Children's Hospital/Carolinas Healthcare System, Charlotte, NC, ¹⁸Nationwide Children's Hospital, Columbus, OH, ¹⁹Cincinnati Children's Hospital Medical Centre, Cincinnati, OH, ²⁰Cincinnati Children's Hospital, Cincinnati, OH, ²¹Hackensack University Medical Center, Hackensack, NJ, ²²Texas Children's Hospital/Baylor College of Medicine, Houston, TX, ²³Seattle Children's Hospital, Seattle, WA
Background/Purpose: Treat to target (T2T) is a strategy of adjusting treatment until a therapeutic target is reached. There is growing evidence supporting the use and…
Abstract Number: 0627 • ACR Convergence 2021
Increasing Rates of Standardized Depression Screening in Adolescents and Young Adults with Childhood-Onset Systemic Lupus Erythematosus in a Pediatric Rheumatology Clinic
Emily Datyner¹, Manda Mitchell¹, Brooke Fine¹, Barron Patterson¹, T. Brent Graham¹ and Alaina Davis², ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt Universty Medical Center, Nashville, TN
Background/Purpose: Depression is common and adversely affects health outcomes in adolescents and young adults with childhood-onset systemic lupus erythematous (cSLE).1,2 The aim of our quality…
Abstract Number: 0657 • ACR Convergence 2021
Assessing Patient Transition Outcomes from a Large Pediatric Rheumatology Center to Adult Healthcare
Mary Robichaux¹, Bernard Danna², Monique Maher², David McDonald¹, Kristiana Nasto¹, Alexander Alexander¹, Ariel Coleman³, Danielle Guffey¹ and Tiphanie Vogel¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Texas Children's Hospital, Houston, TX
Background/Purpose: Transitioning children with chronic diseases from pediatric to adult healthcare can be a challenging task, with high morbidity and mortality. In response, we have…
Abstract Number: 037 • 2020 Pediatric Rheumatology Symposium
Improving Pneumococcal Vaccination Rates in Immunosuppressed Rheumatology Patients
Julia Harris¹, Michael Holland ², Emily Fox ², Amy Ivy ², Maria Ibarra ², Cara Hoffart ², Jordan Jones ², Leslie Favier ³ and Ashley Cooper ², ¹Children's Mercy Kansas City, Overland Park, ²Children's Mercy Kansas City, Kansas City, ³Children's Mercy Kansas City, Leawood
Background/Purpose: The Centers for Disease Control and Prevention recommends pneumococcal vaccination of high-risk patients, including patients on iatrogenic immunosuppression. Many patients seen in the rheumatology…
Abstract Number: 039 • 2020 Pediatric Rheumatology Symposium
Assessing Patient Self-Reported Transition Readiness in a Large Pediatric Rheumatology Center
Priyanka Moolchandani ¹, Alexander Alexander ¹, Cristina Saez ¹, JaLeen Rogers ², Ariel Coleman ², Anne Dykes ², Miriah Gillispie-Taylor ³ and Tiphanie Vogel¹, ¹Baylor College of Medicine, Houston, ²Texas Children's Hospital, Houston, ³Levine Children's Hospital, Charlotte
Background/Purpose: Patients with childhood-onset rheumatologic diseases live well into adulthood and need effective transition from pediatric to adult medical providers. Fortunately, predictors of successful transition…
Abstract Number: 086 • 2020 Pediatric Rheumatology Symposium
Advanced Multidisciplinary Care: A New Approach to Childhood Arthritis
Julia Brooks¹, Dorothy Adams ², Robin Hellweg ¹, Maggie Mercer ¹, Joni Shair ², Dwaraka Veeramreddy ³, Aynsley Wennberg ¹ and Heinrike Schmeling ⁴, ¹Alberta Children's Hospital, Calgary, Alberta, Canada, ²Alberta Children's Hospital, Calgary, Canada, ³Alberta Children's Hospital/University of Calgary, Calgary, Canada, ⁴Alberta Children's Hospital/University of Calgary, Calgary, Alberta, Canada
Background/Purpose: Many patients are overwhelmed with the diagnosis of chronic childhood arthritis and require long-term treatments. Our objective was to develop a new, child and…
Abstract Number: 173 • 2020 Pediatric Rheumatology Symposium
Impact of a Nutrition-Focused Quality Improvement Intervention on Hospital Readmission Rates in Henoch-Schönlein Purpura with Gastrointestinal Involvement
Maria Pereira¹, Miriah Gillispie-Taylor ², Pooja Patel ³, Michael Nelson ⁴, Ugo Awa ⁴, Monica Bray ⁵, Amanda Brown ⁴, Andrea Ramirez ⁶, MaiLan Nguyen ⁴, Saimun Singla ⁴, Tiphanie Vogel ⁴, Eyal Muscal ⁵, Marietta De Guzman ⁶, Elisabeth Hastings ⁷, Ashleigh Russell ⁷ and Kristina Lakenmacher ⁷, ¹Assistant Professor, Section of Rheumatology, Division of Pediatrics, Baylor College of Medicine, Houston, Texas, ²Levine Children's Hospital, Charlotte, ³Baylor College of Medicine, Houston, Texas, ⁴Baylor College of Medicine, Houston, ⁵Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, ⁶Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, ⁷Texas Children's Hospital, Houston
Background/Purpose: Henoch-Schönlein Purpura (HScP) is the most common form of vasculitis in children, with gastrointestinal (GI) complaints occurring in more than a third of patients…
Abstract Number: 174 • 2020 Pediatric Rheumatology Symposium
Improving Hospital Discharge Instructions for Pediatric Rheumatology Patients
Laura Ballenger¹, Vidya Sivaraman ², Stephanie Lemle ³ and Kyla Driest ¹, ¹Division of Rheumatology, Nationwide Children's Hospital, Columbus, ²Division of Rheumatology, Nationwide Children's Hospital, Bexley, ³Quality Improvement Services, Nationwide Children's Hospital, Columbus
Background/Purpose: Communication, including clear discharge instructions, is a crucial aspect of the hospital discharge process. Development of standardized discharge templates has been reported to improve…
Abstract Number: 190 • 2020 Pediatric Rheumatology Symposium
Outcomes of an Evidence Based Guideline for the Treatment of Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome
Kacie Hoyt¹, Olha Halyabar ², Joseph Han ³, Siobhan Case ⁴, Margaret Chang ⁵, Ezra Cohen ⁶, Fatma Dedeoglu ⁵, Mark Gorman ⁷, Jonathan Hausmann ⁸, Erin Janssen ², Pui Lee ⁹, Jeffrey Lo ⁵, Mindy Lo ⁵, Esra Meidan ¹⁰, Peter Nigrovic ¹, Jordan Roberts ⁵, Mary Beth Son ¹, Robert Sundel ², Barbara Degar ⁵, Melissa Hazen ⁷ and Lauren Henderson ¹¹, ¹Boston Children's Hospital, Boston, Massachusetts, ²Children's Hospital/Boston Medical Center, Boston, ³Mount Sinai School of Medicine, New York, ⁴Brigham and Women's Hospital, Boston, Massachusetts, ⁵Boston Children's Hospital, Boston, ⁶, ⁷Boston, ⁸Division of Immunology, Boston Children's Hospital; Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, ⁹Boston Children's Hospital, Newton, ¹⁰Somerville, ¹¹Boston Children's Hospital, Watertown, Massachusetts
Background/Purpose: Rapid identification of hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) coupled with a multidisciplinary approach to management is essential to improve patient outcomes.…
Abstract Number: 192 • 2020 Pediatric Rheumatology Symposium
Single Center Consensus of Prophylactic Treatment in Immunocompromised Children with Rheumatic Disease
Stephen Wong¹, Amy Gaultney ² and Deborah McCurdy ³, ¹University of California Los Angeles, Los Angeles, California, ²UCLA, Los Angeles, California, ³UCLA Medical Center, Los Angeles, California
Background/Purpose: Many children with rheumatic diseases require immunosuppressive treatments, however these medications put them at risk for contracting opportunistic infections leading to severe morbidity and…
Abstract Number: 006 • 2020 Pediatric Rheumatology Symposium
Increasing Rates of Standardized Depression Screening in Youth with Systemic Lupus Erythematosus in a Pediatric Rheumatology Clinic
Victoria Newsome ¹, Jodi Dingle ², Manda Mitchell ³, Thomas Brent Graham ⁴ and Alaina Davis⁵, ¹Nashville, ²Vanderbilt University Medical Center, Nashville, Tennessee, ³Nashville, Tennessee, ⁴Vanderbilt University Medical Center, Nashville, ⁵Monroe Carell Jr. Children’s Hospital at Vanderbilt, Nashville, Tennessee
Background/Purpose: Depression is common among youth with SLE. Early identification and treatment of depression has the potential to improve health outcomes for youth with SLE.…
Abstract Number: 320 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine (HCQ) Prescribing Habits and Provider Opinion on Dosing Guidelines in the Rheumatology and Dermatology Practices of an Academic Institution
Rebecca Overbury¹, Jakrapun Pupaibool ², Christopher Hansen ³, Daniel Clegg ⁴ and Dorota Lebiedz-Odrobina ⁵, ¹Assisstant Professor, University of Utah, Salt Lake City, UT, ²University of Utah, Division of Infectious Diseases, Salt Lake City, UT, ³University of Utah, Department of Dermatology, Salt Lake City, UT, ⁴University of Utah, Salt Lake City, UT, ⁵University of Utah, Division of Rheumatology, Salt Lake City, UT
Background/Purpose: Research has shown potential retinal toxicity rates from HCQ as high as 7.5%. Research suggests toxicity is dose-related. In 2016, the American Academy of…
Abstract Number: 321 • 2019 ACR/ARP Annual Meeting
Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Rheumatoid Arthritis and Systemic Lupus Erythematosus
Tara Skorupa¹ and Robert Shmerling ¹, ¹Beth Israel Deaconess Medical Center / Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly prescribed medication for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other rheumatic diseases. However, HCQ may cause retinal…
Abstract Number: 322 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Retinal Screening and Dosing in an Unique Rheumatologic Patient Population
Leanna Wise¹, Stavros Savvas ² and Elizabeth Ortiz ², ¹LAC+USC/Keck Medicine of USC, Los Angeles, CA, ²LAC+USC/Keck Medicine of USC, Los Angeles
Background/Purpose: Hydroxychloroquine (HCQ) is used in many rheumatologic diseases. The American Academy of Ophthalmology (AAO) put forth guidelines in 2012 regarding retinal screening and dosing…
Abstract Number: 324 • 2019 ACR/ARP Annual Meeting
Adherence to Guideline Directed Management of Gout Among VA Providers
Kelly Corbitt ¹, Isis Lopez² and David Dillon ³, ¹University of Miami/Jackson Memorial Hospital, Miami, FL, ²University of Miami/ Jackson Memorial Hospital, Miami, FL, ³University of Miami/Jackson Memorial Hospital, Miami
Background/Purpose: Gout is the most common inflammatory arthritis, affecting about 4% of the adult population in the United States. Management is often costly, with estimates around…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].